Close this search box.

We are creating some awesome events for you. Kindly bear with us.

UniSA Develops First-iIn-Human Trial for Aggressive Brain Tumours

A novel technology designed to precisely image aggressive brain cancers and guide treatment is being developed by the University of South Australia and an Australian cancer diagnostic company potentially helping thousands of people who are diagnosed with the deadly condition each year. The new MRI nanotechnology targets a specific marker that is found in more than 90% of solid tumours, including high-grade brain cancers.

Already yielding promising preclinical results in a prostate cancer model, the new MRI technology has the potential to have a significant impact on aggressive brain cancers. The new funding will progress the technology towards a first-in-human trial.

UniSA’s Dr Nicole Dmochowska will lead the research, supported by a REDI Fellowship, announced recently. Dr Dmochowska says there is a critical need for better imaging of high-grade brain tumours. She noted that the prognosis for high-grade brain tumours such as glioblastoma remains abysmal, so new technologies that can potentially enable more precise targeting of tumours must be progressed.

The REDI Fellowship program provides financial support to companies in the medical technology, biotechnology and pharmaceuticals (MTP) sector to bring researchers, clinicians and MTP professionals in-house for up to twelve months to work on priority medical research projects.

This research will advance a cutting-edge imaging technology developed in collaboration with the partnering company and with the support of the NeuroSurgical Research Foundation designed to more accurately image and, therefore, treat brain tumours with no additional neurotoxicity.

Dr Hien Le, a radiation oncologist at the Royal Adelaide Hospital and one of the Chief Investigators in the seed funding for this work, says the research has the potential to advance cancer treatments. “As someone who specialises in the management of brain cancer, I understand the importance of accurate tumour delineation.”

It was noted that better imaging means the tumour target can be more confidently defined, precise treatment delivery can be facilitated, whilst damage to normal healthy tissues can be minimised. In 2021, there were 1896 new diagnoses of brain cancer (1191 males and 725 females). Glioblastoma is the most common brain malignancy with a five-year survival rate of only 5%.

The R&D Manager at the company stated that the research will streamline preclinical validations for the technology for brain tumours, in preparation for a phase 1 ‘first-in-human’ clinical trial. She noted that the company is determined to transform the precision of cancer imaging, surgery and therapy to ensure that everyone diagnosed with cancer is given the best possible care.

The new technology builds on the firm’s cancer staging technology FerroTrace currently undergoing clinical trials in several cancer types. By bringing together the best minds in chemistry, bioengineering and oncology, the firm is continuing to push the boundaries to help make sure no one dies unnecessarily because the cancer was missed.

The global cancer diagnostics market size was valued at us$ 168 billion in 2020 and is projected to reach us$ 280 billion by 2028, registering a CAGR of 6.9% from 2021 to 2028. Cancer diagnostics is a method of identifying different biomarkers, proteins, and some signs that lead to the identification of the presence of a cancerous tumour.

Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule and review treatment outcomes. Diagnostic procedures for cancer may include imaging, tumour biopsy, laboratory tests (including tests for tumour markers), endoscopic examination, surgery or genetic testing.

Nationwide lockdown, government regulations, and continuous increase in infection rates across countries created a widespread financial impact on neurology hospitals and clinics.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.